MARK E. GURNEY PHD MBA
Chairman & CEO, Tetra Discovery Partners Inc.
Dr. Mark Gurney founded Tetra Discovery Partners as a drug development company in 2011 to develop meaningful medications for large unmet needs including Alzheimer’s disease. He has held positions in academia and within the pharma industry. Dr. Gurney was named one of two leading inventors in the field of Alzheimer’s Disease therapeutics for his discovery of the beta-secretase, a key enzyme in the amyloid pathway that releases the A-beta peptide from the amyloid protein precursor.
Dr. Gurney’s resume with biotech companies includes work in drug discovery and development as Senior Vice President at deCODE genetics, Inc.; Director Genomics, Pharmacia Corporation; Associate Professor, Northwestern University Feinberg School of Medicine; and Assistant Professor, University of Chicago Medical School. In addition to his work on Alzheimer’s disease, Dr. Gurney developed the SOD1-G93A transgenic mouse model of ALS.
Dr. Gurney has authored 117 peer reviewed papers that have been cited over 26,000 times and holds 36 issued patents. He earned a PhD in neuroscience from the California Institute of Technology and an MBA from the Kellogg Graduate School of Management at Northwestern University.
Chief Business Officer, Director of the Board
Joe Collard is the Founder/CEO of Epigenetix, which uses epigenetic pathways to solve unmet medical needs including the treatment of brain cancer. An exited entrepreneur, he also built and sold three successful science/technology companies, namely Technisource, Curna Inc., and Sumpraxis.
Mr. Collard holds a Bachelor of Business Administration degree from the University of Michigan-Flint.
CHAD A. COBERLY JD
Sr. VP Clinical, Regulatory & Legal Affairs
Chad has more than 25 years of experience, primarily in the areas of biotech regulatory, clinical, compliance, intellectual property, business development, litigation, and general corporate legal affairs. Prior to joining Tetra he served as the Chief Clinical & Legal Officer for Cohera Medical, where he led the clinical, regulatory and legal aspects of commercialization of the first ever approved 100% synthetic absorbable surgical adhesive. He brings intellectual property experience from the law firm of Howard and Howard, and experience from Zassi Medical and the Surgical Group of the Stryker Corporation where he held regulatory and legal related positions.
Chad holds a JD. from Michigan State University and a bachelor’s degree in biomedical engineering from Tulane University. He also has conducted MBA studies at Boston University. He is admitted to practice before the U.S. Patent and Trademark Office and is a member of the Michigan Bar.
SCOTT A. REINES MD PHD
Chief Medical Officer
Dr. Scott A. Reines has broad drug development experience obtained as a senior executive in pharmaceutical R&D. As Senior Vice President for CNS, Pain, and Translational Medicine at Johnson & Johnson, he oversaw the development and approval of numerous medicines for the treatment of schizophrenia, Alzheimer’s disease, and the behavioral manifestations of autism.
Prior to that, Dr. Reines served at Merck as Vice President, Clinical Research, with responsibilities for Psychopharmacology, Neuropharmacology, Gastroenterology, and Ophthalmology. While there, he oversaw the conduct of the first large, multicenter trial of a COX-2 inhibitor for prevention of Alzheimer’s disease.
Dr. Reines earned a BS magna cum laude in chemistry from Cornell University, his PhD in bio/organic chemistry from Columbia University, and his MD from Albert Einstein College of Medicine. Following this he completed a psychiatric residency at Montefiore Hospital in New York City and obtained Board certification in psychiatry.
Chief Financial Officer
Mr. Harvey Elgersma has more than 30 years of diversified experience in financial leadership. His CFO experience includes multiple mergers and acquisitions, strategies for increasing value, and developing both successful exit and growth strategies. Mr. Elgersma has worked with Perrigo; CHS, Inc.; Hamilton Farm Bureau Cooperative, Inc. and Cumberland Swan Holding Inc.
Mr. Elgersma holds a BBA in accounting from Grand Valley State University.
BRIAN MARRON PHD
Vice President, Chemistry
Dr. Brian Marron brings over 28 years of leadership in medicinal chemistry and drug discovery to Tetra Discovery Partners. Prior to joining Tetra he was a drug discovery consultant. Before consulting Brian was Director, Worldwide Medicinal Chemistry for Pfizer where he led the North Carolina based chemistry and bioanalytical teams after Pfizer acquired Icagen, Inc. As a Senior Director of Chemistry at Icagen he led early discovery chemistry and chemistry teams in Icagen’s collaborations with Pfizer and Abbott and was involved in development activities for Icagen’s clinical epilepsy compounds. While at Icagen with collaborators he played key scientific and leadership roles in the discovery of selective Nav1.8 inhibitors and first in class selective Nav1.7 inhibitors. He began his career at GSK where he rose to Senior Research Investigator, contributing to several projects including the early discovery and lead optimization efforts for 7TM GPCR targets. Brian has been part of the discovery of several pre-clinical and clinical compounds.
Dr. Marron holds a PhD from University of Pennsylvania. He conducted postdoctoral work at the University of Wisconsin-Madison, and earned his BS in chemistry from the University of Idaho. Brian has more than eighty patents, papers, posters and presentations.
RICHARD NUGENT PHD
Dr. Richard Nugent leads programs for the CNS application of PDE4 inhibitors for Tetra. Prior to this work, he worked on projects aimed at treating cystic fibrosis for Flatley Discovery Labs and drug discovery projects against inflammation, osteoporosis, and metabolic diseases as well as anti-infectives and applications of siRNA for Pfizer. He has also worked for Pharmacia and Upjohn.
Dr. Nugent earned his BS from Miami University and his PhD in organic chemistry from the University of Rochester.
RYUICHI KIYAMA PHD
Director of the Board
Dr. Ryuichi Kiyama joined Shionogi & Co., Ltd. in 1989 and is Corporate Officer, Senior Vice President, Pharmaceutical Research Division. In his tenure with Shionogi, he has led the organization in multiple capacities including 12 years in corporate strategy and business development. He has completed a wide range of transactions with global pharmaceutical and biotechnology companies including licensing agreements, equity investments, academic collaborations, and option structures. He was President & CEO of Ezose Science Inc., a New Jersey based biotech company of glycomics, then successfully transferred the business to Sumitomo Bakelite Co., Ltd. Prior to that, in his 20-year scientific career as a research scientist in infectious disease, he led the discovery research of clinical candidates such as Doltegravir (brand name; Tivicay), a HIV integrase inhibitor.
Dr. Kiyama was a Visiting Scientist at the Scripps Research Institute in San Diego and has authored or co-authored 14 peer-reviewed scientific publications. He holds his PhD in Medicinal Chemistry from the Kyushu University.
DOUGLAS MORTON JR PHD
Director of the Board
Dr. Douglas Morton has 40 years of experience in the pharmaceutical industry. Formerly a Vice President in the Discovery Division of Pfizer, Dr. Morton also held executive positions with Pharmacia Corporation and Upjohn, Inc.
A published scientist and prolific inventor, Dr. Morton has authored or co-authored 45 peer-reviewed scientific publications and holds 43 U.S. Patents. He currently sits on the board of 5 biotechnology companies and on the advisory boards of Cleveland Clinic Innovations, Hopen Lifescience Venture Fund, and the Southwest Michigan First Life Science Fund.
Dr. Morton received his AB in chemistry from Kenyon College and his PhD in chemistry from Columbia University.
LANCE STEWART PHD MBA
Director of the Board
Dr. Lance Stewart is the Chief Strategy and Operations Officer for the Institute for Protein Design at the University of Washington School of Medicine and brings over 23 years of experience in drug discovery, corporate partnerships and entrepreneurial start-up activities. He co-founded Emerald BioStructures in 1998 as a UW spinout company (now division of UCB Pharma) and led the growth of the company as a business unit within two publicly traded companies and the successful exit from deCODE Genetics in 2009. Based on technology developed during the Protein Structure Initiative, he co-founded Emerald BioSystems in 2005 (now a Rigaku company). Dr. Stewart served for 2 years (2012 to 2014) as the Sr. Director of Alliances at the Allen Institute for Brain Science. He has co-authored 93 peer-reviewed scientific publications and five book chapters and is an inventor on nine issued U.S. patents.
Dr. Stewart holds a bachelor’s degree in biology from McMaster University and a doctorate in biochemistry and virology from Cornell University. He also earned an Executive Master of Business Administration from the Foster School at the University of Washington.
EDWARD M. SCOLNICK MD
Scientific Advisory Board
Dr. Edward M. Scolnick joined the Broad Institute of MIT in 2004 to spearhead a major research effort in psychiatric disease and in 2007 became the director of Broad’s Psychiatric Disease Program and founding director of the Stanley Center for Psychiatric Research. Dr. Scolnick served as the Stanley Center’s director for five years, and currently serves as the center’s chief scientist.
From 1982 to 2003, Dr. Scolnick served as president of Merck Research Laboratories; executive vice president for science and technology at Merck & Co., Inc.; executive director and vice president in the department of virus and cell biology and senior vice president for basic research at Merck Research Laboratories.
Prior to joining Merck, he worked at the National Cancer Institute and at the National Heart Institute.
Dr. Scolnick is an elected member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine.
He served on the Board of Directors of Merck & Co., Inc. from 1997 to 2002; the Board of Councilors for the National Institute of Mental Health from 1998 to 2002; and the FDA Science Board from 2000 to 2002. He currently is a consultant for Clarus Ventures.
Dr. Scolnick holds an A.B. from Harvard College and an M.D. from Harvard University Medical School.
JAMES S. MACDONALD PHD
Scientific Advisory Board
Dr. James S. MacDonald, a co-founder of the Synergy Partners network, provides consultation in the clinical trial phase of drug development.
He retired from Schering-Plough as Executive Vice President of Preclinical Development, where he assured a steady flow of new compounds through the development pipeline by establishing effective working relationships with appropriate groups in Discovery, Pharmaceutical Sciences and Global Clinical Research. Prior to that, Dr. MacDonald was Executive Director of Toxicology at Merck Research Laboratories. During his career at both of these companies he was responsible for numerous important human medicines now registered for global marketing.
Dr. MacDonald received his undergraduate degree from DePauw University and his PhD in toxicology from the University of Cincinnati.
CATHERINE D. STRADER PHD
Scientific Advisory Board
Dr. Catherine D. Strader has more than 25 years of pharmaceutical R&D experience including executive leadership positions at both Merck and Schering-Plough. She has guided more than 50 compounds through drug discovery.
Dr. Strader began her career at Merck, where she led the team that first defined the structure-function of G-protein coupled receptors. As Executive Vice President of Discovery Research and Chief Scientific Officer for Schering-Plough, Dr. Strader had both strategic and operational responsibility for the company’s global small molecule and biologics discovery research portfolio. In 2007 Dr. Strader returned to Merck to lead an external research initiative, integrating large pharma, biotech and CRO approaches to drug discovery. She co-founded Synergy Partners to integrate the depth and breadth of experience required to effectively bring new discoveries to clinical proof of concept and beyond.
Dr. Strader received her BS in chemistry from the University of Virginia and her PhD in chemistry from the California Institute of Technology.